Assessment of Interactions Between Methamphetamine and Aripiprazole - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: August 5, 2004
Last updated: October 25, 2007
Last verified: July 2005
The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.
||Primary Purpose: Treatment
||Assessment of Interactions Between IV Methamphetamine and Aripiprazole
Primary Outcome Measures:
- Adverse effect measures
- pharmacokinetic assessment
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
- Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.
- Please contact the site for more information.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00089440
|UCLA Integrated Substance Abuse Program
|Los Angeles, California, United States, 90024 |
|New York University, School of Medicine
|New York, New York, United States, 10016 |
||Thomas Newton, M.D.
||University of California, Los Angeles
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 5, 2004
||October 25, 2007
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 22, 2014
Adrenergic Uptake Inhibitors
Central Nervous System Agents
Central Nervous System Depressants
Central Nervous System Stimulants
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs